0.970
0.05 (5.42%)
| Penutupan Terdahulu | 0.920 |
| Buka | 0.929 |
| Jumlah Dagangan | 373,734 |
| Purata Dagangan (3B) | 498,315 |
| Modal Pasaran | 65,714,716 |
| Harga / Jualan (P/S) | 840.89 |
| Harga / Buku (P/B) | 1.22 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 19 Mar 2026 |
| Margin Operasi (TTM) | -41,252.01% |
| EPS Cair (TTM) | -0.870 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 103.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.00% |
| Nisbah Semasa (MRQ) | 5.28 |
| Aliran Tunai Operasi (OCF TTM) | -47.70 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 34.37 M |
| Pulangan Atas Aset (ROA TTM) | -34.47% |
| Pulangan Atas Ekuiti (ROE TTM) | -54.13% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | InflaRx N.V. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | 2.0 |
| Purata | 2.13 |
|
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 6.44% |
| % Dimiliki oleh Institusi | 26.24% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Dcf Advisers, Llc | 31 Dec 2025 | 158,500 |
| Julat 52 Minggu | ||
| Median | 6.00 (518.56%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 30 Dec 2025 | 6.00 (518.56%) | Beli | 1.02 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 29 Jan 2026 | Pengumuman | InflaRx Announces Participation in February Investor Conferences |
| 08 Jan 2026 | Pengumuman | InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation |
| 30 Dec 2025 | Pengumuman | InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |